Pricing Log in Create free account
Friday 6 November 2026 Export CRSP’s income statement to Excel — free account

CRISPR Therapeutics AG

CRSP Healthcare Biotechnology

CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.

Revenue
+1,325.1%
EPS
+1.55%
Free cash flow
−6.36%

Quarter to September 2026, against a year earlier

49.92 1.36 +2.80%
Market cap
$4.7B
P/E
0.0×
Fwd P/E
−11.8×
Dividend yield
—
F-score
2/9
Altman Z
7.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

CRISPR Therapeutics AG (CRSP) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, CRISPR Therapeutics AG (CRSP) trades at a EV/Sales of 125×. Over the past ten years it has ranged from −26.0× (February 2017) to 16,984× (January 2021); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 845× 1,819.01%
FY2024 44.0× 334.09%
FY2023 10.1× (99.24%)
FY2022 1,336× 33,951.78%
FY2021 3.9× (99.97%)
FY2020 11,763× 141,051.13%
FY2019 8.3× (97.15%)
FY2018 292× 1,460.29%
FY2017 18.7× —
FY2016 −7.7× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 146× (44.04%)
Jun 2026 260× (60.63%)
Mar 2026 661× (21.78%)
Dec 2025 845× 666.28%
38 more quarters

Against its own ten years

Low −26.0× High 16,984×
Ten-year median 43.3×
Current reading's percentile 70

EV/Sales against peers

Company EV/Sales
EWTX Edgewise Therapeutics, Inc. compare n/m
DFTX Definium Therapeutics, Inc. compare n/m
ERAS Erasca, Inc. compare n/m
MANE Veradermics Incorporated compare n/m
LEGN Legend Biotech Corporation Sponsored ADR compare 2.9×
TVTX Travere Therapeutics, Inc. compare 7.4×
CRSP CRISPR Therapeutics AG 125×
COGT Cogent Biosciences, Inc. compare 209×
DNTH Dianthus Therapeutics, Inc. compare 1,515×
Biotechnology industry median 9.0×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CRSP